GeneDx Faces Securities Class Action Over Alleged Misleading Financials

The complaint centers on claims that GeneDx misled the market during the specified class period. According to the filing, the company’s public disclosures failed to accurately reflect its underlying financial position, specifically highlighting a notable decline in adjusted gross margins during the first quarter of 2026. This performance shortfall ultimately forced the company to downwardly revise its projected full-year earnings, contradicting earlier statements provided to shareholders.

The DJS Law Group is currently soliciting investors who suffered losses to consider serving as lead plaintiffs. While legal representation is seeking to hold the company accountable for these discrepancies, the firm notes that shareholders are not required to take on a lead role to participate in potential financial recoveries. The litigation, filed under sections 10(b) and 20(a) of the Securities Exchange Act of 1934, targets the company’s alleged failure to maintain transparency with its investors.